ArticleCureus2026
Early Tranexamic Acid Therapy and Its Influence on Hemoglobin Dynamics, Hospital Stay, and ICU Admissions in Upper Gastrointestinal Bleeding.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Upper gastrointestinal bleeding (UGIB) is a life-threatening emergency associated with substantial morbidity, frequent transfusion needs, and prolonged hospitalization. Tranexamic acid (TXA) may reduce bleeding by stabilizing fibrin clots, but evidence regarding its early use in UGIB remains mixed. Objective This study evaluated whether early TXA administration influences hemoglobin dynamics, hospital stay, and ICU admissions in patients presenting with UGIB. Methods This prospective observational study was conducted at Shifa International Hospital, Islamabad, Pakistan, over 24 months. A total of 220 adult patients with UGIB were enrolled through purposive sampling and divided into two equal groups: an early TXA group receiving intravenous TXA within six hours of presentation (n=110) and a control group receiving standard care (n=110). Baseline demographic and clinical characteristics were similar between groups. Primary outcomes included hemoglobin levels at baseline, 24 hours, 48 hours, and discharge. Secondary outcomes included hospital length of stay, ICU admissions, blood transfusion requirements, and in-hospital mortality. Multivariable regression analyses were performed to adjust for age, comorbidities, baseline hemoglobin, bleeding source, and endoscopic interventions. Results Early TXA significantly preserved hemoglobin at 24 hours (9.2 ± 1.4 vs. 8.5 ± 1.6 g/dL, p < 0.001), 48 hours (8.9 ± 1.3 vs. 8.1 ± 1.5 g/dL, p < 0.001), and discharge (9.0 ± 1.2 vs. 8.2 ± 1.4 g/dL, p < 0.001). Hospital stay was shorter with TXA (5 (4-7) vs. 7 (5-9) days, p < 0.001), and ICU admissions were lower (10.9% vs. 23.6%, p = 0.008). TXA-treated patients required fewer transfusions (1.2 ± 0.8 vs. 2.0 ± 1.1 units, p < 0.001). Mortality was lower but not statistically significant (3.6% vs. 7.3%, p = 0.25). Multivariable analysis confirmed independent associations between early TXA and reduced hemoglobin drop, shorter hospital stay, and lower ICU admission odds. Conclusion Early TXA administration improves hemoglobin preservation, reduces transfusion needs, shortens hospitalization, and lowers ICU admissions in UGIB, supporting its role as an effective early adjunct in acute management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.